The Life Sciences team advised Mr. Pablo Legorreta, the founder and CEO of Royalty Pharma, as lead investor in ITBMed’s $67 million equity financing round. The capital injection will be used to develop ITBMed’s Siplizumab, in its lead indication of induction of tolerance in organ transplantation, where it has been successfully used in a phase II trial to permit organ transplants without the need of lifelong immunosuppression.
ITBMed is a biopharmaceutical company focusing on the development of specific immunomodulatory biologics for use primarily in organ and stem cell transplantation.
The Goodwin team was led by partner Robert Puopolo and included partner Kingsley Taft.
For more details on the financing, please read the press release.